RT Journal Article SR Electronic T1 Continuity Unveiled: Evaluating Cytoreduction Outcomes for Advanced Ovarian Cancer Amidst the COVID-19 Era at an ESGO Designated Centre of Excellence JF Anticancer Research JO Anticancer Res FD International Institute of Anticancer Research SP 2645 OP 2652 DO 10.21873/anticanres.17071 VO 44 IS 6 A1 KITSOS-KALYVIANAKIS, KONSTANTINOS A1 PITSIKAKIS, KONSTANTINOS A1 MAMALIS, MARIOS EVANGELOS A1 KALAMPOKIS, EVANGELOS A1 TAN, YONG SHENG A1 THANGAVELU, AMUDHA A1 BROADHEAD, TIMOTHY A1 NUGENT, DAVID A1 DEJONG, DIEDERICK A1 LAIOS, ALEXANDROS YR 2024 UL http://ar.iiarjournals.org/content/44/6/2645.abstract AB Background/Aim: The COVID-19 pandemic brought unprecedented global changes, necessitating adjustments to address public health challenges. The impact on advanced epithelial ovarian cancer (EOC) surgery, marked by increased perioperative risks, and changes in management plans was explored in this study based on promptly published British Gynaecologic Cancer Society (BGCS) and European Society of Gynaecologic Oncology (ESGO) guidelines. Patients and Methods: Retrospective data from 332 patients with advanced EOC who underwent cytoreductive surgery at a UK tertiary center were analyzed, and the outcomes were compared between pre-COVID-19 (2018-2019) (n=189) and COVID-19 era (2020-2021) (n=143) cohorts, covering the same timeframe (March to December). Primary outcomes included residual disease (RD) and progression-free survival (PFS), while secondary outcomes were the ESGO quality indicators (QIs) for advanced EOC surgery. Kaplan–Meier curves were produced to illustrate PFS. Results: Complete cytoreduction rates remained comparable at 74.07% and 72.03% for pre-COVID-19 and COVID-19 groups, respectively. Differences were observed in ECOG performance status (p=0.015), Intensive Care Unit (ICU) admissions (p=0.039) with less interval debulking surgeries (p=0.03), lower surgical complexity scores (p=0.02), and longer operative times in the COVID-19 group (p=0.01) compared to the pre-COVID-19 group. The median PFS rates were 37 months and 34 months in the pre-COVID-19 and COVID-19 groups, respectively (p=0.08). The surgical QIs 1-3 remained uncompromised during the COVID-19 era. Conclusion: Management modifications prompted by the COVID-19 pandemic did not adversely impact cytoreduction rates or PFS.